Plasmodium Knowlesi As A Genetic Model For Plasmodium Vivax Drug Resistance
Funder
National Health and Medical Research Council
Funding Amount
$417,193.00
Summary
Two different Plasmodium parasites cause the majority of malaria worldwide. However, one type, P. vivax, is unable to be cultured in the laboratory and therefore has been poorly studied. Drug resistance has been observed but the underlying causes are poorly understood. We propose to use a closely related parasite, P. knowlesi, as a model to understand drug resistance mechanisms. This knowledge will be used to follow resistance in the field and direct policy of the most appropriate treatment.
Development Of Novel Anti-malaria Drugs That Block Parasite Invasion
Funder
National Health and Medical Research Council
Funding Amount
$1,035,623.00
Summary
Malaria is a devastating parasitic disease that kills over 400,000 people a year. Antimalarial drugs play a crucial role in helping eradicate malaria but of great concern is that parasites are becoming resistant to current drugs. We are developing drugs that prevent parasites from invading and proliferating in human blood which causes malaria. We are also discovering how the drugs work with the aim of greatly improving their performance towards clinical uptake.
Disease Burden, Risk Factors And Treatment Of Knowlesi Malaria
Funder
National Health and Medical Research Council
Funding Amount
$95,564.00
Summary
Plasmodium knowlesi is a form of monkey malaria recently found to also cause increasing numbers of natural infections in humans in South-East Asia. This research will describe the burden of P. knowlesi malaria in an area of Malaysian Borneo. The risk factors for acquiring P. knowlesi malaria will be assessed. Finally the optimal treatment for non-severe cases of P. knowlesi and P. vivax malaria will also be evaluated by comparing the 2 currently recommended anti-malarial medications in Malaysia.
Griseofulvin, A Novel Host-directed Antimalarial Drug
Funder
National Health and Medical Research Council
Funding Amount
$461,551.00
Summary
This grant is for a Phase II clinical trial to test an FDA & TGA approved drug for a new use as an antimalarial drug. The parasite uses an enzyme from the human RBC to help it replicate & early trials show this drug appears to disrupt the life cycle of the parasite. This Phase II clinical trial will test the drug on human subjects, & if successful, the drug will be a new and novel way in which to treat and prevent malarial infections in humans.
Over the next 5 years my team and I plan to study parasite invasion and blood cell enslavement to guide the design of better vaccines and medicines. Malaria as a deadly parasitic disease caused by large-scale infection of the body’s red blood cells. To design more effective vaccines and improved drugs to globally eliminate malaria we need to improve our understanding of how parasites infect and enslave our blood cells so they can grow rapidly and avoid our immune system.
Enhancing Anti-parasitic Drug Discovery With Metabolomics
Funder
National Health and Medical Research Council
Funding Amount
$483,402.00
Summary
Tropical diseases, such as malaria, infect millions of people each year, and drug resistance is emerging to current treatments. This research will improve our understanding of how current medicines work, and importantly, identify ways in which potential new drugs can kill malaria parasites.
Improving Malaria Elimination Strategies With Genomics: Tackling The Unique Problems Posed By Plasmodium Vivax, And P. Falciparum Drug Resistance
Funder
National Health and Medical Research Council
Funding Amount
$327,193.00
Summary
Malaria parasites are becoming resistant to drugs, and some types can avoid treatment by hiding in the liver and recurring months later. Variation in human genes can also mean that some drugs are dangerous to certain people, or won’t work. DNA sequencing will allow us to understand the interplay between parasite and host genetics and the efficacy of drugs in the population, allowing us to provide ‘personalised’ treatments in that region.
Centre For Research Excellence In Malaria Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,470,291.00
Summary
The CRE will work to accelerate progress towards malaria elimination in our region, through Surveillance, to develop better ways to monitor malaria transmission and discover who is infected, and to track movement of malaria parasites and spread of drug resistance. Diagnosis, to develop and test new, more sensitive ways of detecting malaria. Treatment, to fast track development of new antimalarials, and improve access to ensure all infected people get highly effective drugs.
Malaria And Infectious Diseases In The Asia-Pacific: Drugs, Vaccines And Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$210,873.00
Summary
Dr Karunajeewa is an expert in the treatment of malaria and other infectious diseases that have a major impact on the health of people living in developing countries of the tropical zone of the Asia-Pacific region. His ongoing research aims to develop better ways of diagnosing these infections, defining their relative importance in terms of overall burden of disease, finding optimal drug treatments and testing the effectiveness of new vaccines for their prevention.
Optimising Treatment And Prevention Strategies To Accelerate Malaria Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,163,220.00
Summary
Elimination of malaria requires the assessment of interventions that not only treat individual infections successfully but also prevent disease at a population level. My proposal brings together data science approaches and mathematical modelling to develop new methods to assess antimalarial treatments and radical population interventions, and identify markers of drug resistance, accelerating malaria elimination efforts and building capacity in this emerging cross-disciplinary field.